Compugen (CGEN) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Compugen Announces Significant Share Price Increase
TipRanks37minutes ago
Compugen Updates Filing Structure With Bristol Myers Squibb
TipRanksFeb 15 12:27 ET
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
PR NewswireFeb 4 07:00 ET
Compugen Ltd.'s (NASDAQ:CGEN) Shares Bounce 26% But Its Business Still Trails The Industry
Simply Wall StJan 15 06:20 ET
Oppenheimer Initiates Compugen(CGEN.US) With Buy Rating, Announces Target Price $4
Moomoo NewsJan 13 08:35 ET · Ratings
Compugen Initiated With an Outperform at Oppenheimer
TipRanksJan 13 08:01 ET · Ratings

Comments

Teddy123

Jan 30 23:37

TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse

$AstraZeneca (AZN.US)$ $Compugen (CGEN.US)$
Major Breakthrough: AstraZeneca's New Weapon Against Early-Stage Lung Cancer Enters Final Testing

1

Jaguar8

Jan 8 09:36

NEWS TODAY

$Compugen (CGEN.US)$
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Wednesday, 8th January at 7:00 am
• New approach to harness cytokine biology to treat cancer patients advances to the clinic
• First patient dosed with potential first-in-class anti-IL-18 binding protein antibody, COM503, licensed to Gilead Sciences, Inc.
• Phase 1 dose escalation and dose expansion trial...

4

Jaguar8

Dec 15, 2024 20:58

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...

28

9

7

Jaguar8

Nov 27, 2024 06:03

NEWS

$Compugen (CGEN.US)$
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.
The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduc...

1

Tsukasa0_0

May 30, 2024 22:01

About to Receive Milestone Payment

$Compugen (CGEN.US)$ 🤩
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

CGEN Compugen

Trade Overview

Capital Trend

News

Comments

Trending Stocks